Skip to main content

Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection

Medically reviewed by Carmen Pope, BPharm. Last updated on March 25, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, March 25, 2025 -- For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular residual disease (MRD) precedes disease-free survival (DFS) events in patients receiving osimertinib treatment or placebo and can be used to predict disease recurrence, according to a study published online March 17 in Nature Medicine.

Roy S. Herbst, M.D., Ph.D., from Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and colleagues examined whether tumor-informed, circulating tumor DNA-based MRD could predict recurrence in a post-hoc analysis of 220 patients from the phase 3 ADAURA trial (112 received osimertinib; 108 received placebo).

The researchers found that MRD preceded imaging DFS events by a median of 4.7 months in this study. At 36 months, the DFS and MRD event-free rate was 86 versus 36 percent for patients in the osimertinib and placebo groups (hazard ratio, 0.23). DFS or MRD events were detected in 25 percent of patients (28 patients) in the osimertinib group; most events occurred after cessation of osimertinib (19 of 28 events; 68 percent) and within 12 months of stopping osimertinib (11 of 19 events; 58 percent). The DFS and MRD event-free rate was 66 percent at 24 months after osimertinib.

"Plasma-based, tumor-informed MRD analysis may predict disease recurrence during adjuvant treatment and during posttreatment follow-up," the authors write. "MRD monitoring may inform clinical intervention, including restarting or intensifying treatment."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Similar Survival Seen With Simple Versus Radical Hysterectomy for Cervical Cancer

WEDNESDAY, May 21, 2025 -- For patients with low-risk cervical cancer, survival is similar following simple hysterectomy (SH) versus modified radical hysterectomy (MRH) or radical...

Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy

TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...

Use of Composite Allocation Score for Lung Transplant Wait List Improves Outcomes

MONDAY, May 19, 2025 -- Wait-list outcomes for lung transplants have substantially improved in the composite allocation score (CAS) era, according to a study presented at the...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.